CorVel Corporation (Nasdaq: CRVL) — Form 10-K Summary
Period clarification: The filing provided is CorVel’s annual report for the fiscal year ended March 31, 2022, with comparative results for fiscal 2021 and 2020. It is not a 2020 Q4 filing. The fourth-quarter figures below are for the quarter ended March 31, 2022.
Business context and reporting period
CorVel provides managed-care and medical-cost-containment services, primarily for workers’ compensation, auto, and group-health claims. Its offerings include claims administration, bill review, provider networks, case management, pharmacy, and directed-care services. The company reports one operating segment: managed care.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $646.2 million | $552.6 million | +16.9% |
| Gross profit / margin | $152.1 million / 23.5% | $123.6 million / 22.4% | +23.0%; margin +1.1 points |
| Income before taxes / pretax margin | $84.5 million / 13.0% | $59.2 million / 10.7% | +42.8% |
| Net income / net margin | $66.4 million / 10.2% | $46.4 million / 8.4% | +43.3% |
| Diluted EPS | $3.66 | $2.55 | +43.5% |
| Cash from operations | $67.2 million | $94.4 million | −$27.2 million |
Fiscal 2022 revenue comprised $424.1 million in patient management services (+15%) and $222.2 million in network solutions (+21%). New claims increased 17%. Management attributed growth to economic recovery and greater activity with existing customers, including higher revenue per bill in enhanced bill-review programs.
Fourth-quarter revenue was $171.4 million versus $145.5 million a year earlier; gross profit was $43.1 million versus $35.7 million; net income was $19.6 million versus $14.8 million; and diluted EPS was $1.09 versus $0.81. The filing does not provide quarterly cash-flow figures.
At March 31, 2022, cash and cash equivalents were $97.5 million, working capital was $93.6 million, total assets were $415.2 million, and stockholders’ equity was $212.4 million. Current assets were $265.0 million and current liabilities $171.4 million. CorVel reported virtually no interest-bearing debt historically. Operating cash flow declined partly because the prior-year CARES Act payroll-tax deferral was no longer available, receivables increased, and annual bonuses were paid. Capital spending was $29.8 million, principally for developed software. Cash declined by $42.2 million, with $90.1 million spent on share repurchases.
Material changes versus prior periods
- Revenue rebounded from the 6.7% decline in FY2021, when pandemic-related disruption reduced bill volume 22% and workers’ compensation claims 2.5%.
- Net income rose 43.3% in FY2022, supported by revenue growth and a higher pretax margin; diluted weighted-average shares edged down 0.2%.
- Operating cash flow fell from FY2021’s $94.4 million. Working capital decreased from $106.5 million, primarily reflecting increased share-repurchase spending.
- CorVel repurchased 566,073 shares for approximately $90 million during FY2022. At year-end, 780,375 shares remained authorized for repurchase.
Outlook, commentary, risks, and unusual items
The filing provides no quantified revenue or earnings guidance. Management said cash on hand and anticipated internally generated funds should meet expected requirements for at least 12 months. It may continue repurchases or consider acquisitions, subject to cash generation and board authorization. The company expects a smaller office footprint as more employees work remotely; 62% of employees were permanent work-from-home as of March 31, 2022.
- Key risks include pandemic effects, fewer workplace claims, competition and customer insourcing, contract nonrenewal, wage and benefit inflation, medical-cost inflation, regulatory changes, cybersecurity incidents, litigation, and retaining qualified personnel.
- Management said inflation had not materially affected FY2022 revenue or net income but could materially affect pricing and operating costs in future years.
- CorVel deferred $10.4 million of payroll taxes under the CARES Act; half was repaid in the December 2021 quarter and the remainder was due by calendar year-end 2022. It did not take government loans.
- Ordinary-course litigation was not expected by management to result in material aggregate payments. The auditor issued unqualified opinions on the financial statements and internal control; revenue recognition was identified as a critical audit matter because estimates affect certain bill-review and directed-care revenue.
- The shareholder rights plan expired on February 10, 2022. The company paid no cash dividends and reported no material impairment of goodwill or long-lived assets.
Important facts for investors to verify
- Whether post-pandemic claim volumes, customer activity, and revenue growth are sustainable, and how much growth depends on existing customers versus new business.
- Whether the FY2022 margin improvement persists as headcount, wages, benefits, and other operating costs rise.
- Cash conversion and working-capital trends, including collections on $27.3 million of unbilled receivables and the effect of customer deposits.
- Future capital needs for software development, office leases, and any acquisitions, alongside the pace and price of further share repurchases.
- Progress and risks in reducing office space, and the operational, service, and cybersecurity implications of a largely remote workforce.